Clinical Textbook of Addictive Disorders 3rd ed - R. Frances, S. Miller, A. Mack (Guilford, 2005) WW

8. Marijuana, Hallucinogens, and Club Drugs 181Montoya, A., Sorrentino, R., Lucas, S., & Price, B. (2002). Long-term neuropsychiatricconsequences of “Ecstasy” (MDMA): A review. Harv Rev Psychiatry, 10(4), 212–220.Morgan, M. J. (2000). Ecstasy (MDMA): A review of its possible persistent psychologicaleffects. Psychopharmacology, 152, 230–248.National Eye Institute. (1997, February 18). The use of marijuana for glaucoma. RetrievedFebruary 1, 2004, from www.nei.nih.gov/news/statements/marij.htmNational Institute on Drug Abuse. (1979). Diagnosis and treatment of phencyclidine (PCP)toxicity [Brochure]. Rockville, MD: Author.National Institutes of Health. (1997, February 19–20). Workshop on the medical utilityof marijuana. Retrieved February 1, 2004, from www.nih.gov/news/medmarijuana/medicalmarijuana.htmNelson, K., Walsh, D., Deeter, P., & Sheehan, F. (1994). A phase II study of delta-9-tetrahydrocannabinol for appetite stimulation in cancer-associated anorexia. JPalliat Care, 10, 14–18.Óye, N., Paulsen, O., & Maurset, A. (1992). Effects of ketamine on sensory perception:Evidence for a role of N-methyl D-aspartate receptors. J Pharmacol Exp Ther, 260,1209–1213.Pandit, S. K., Kothary, S. P., & Kumar, S. M. (1980). Low dose intravenous infusiontechnique with ketamine. Anesthesia, 35, 669–675.Peroutka, S. (1990). Ecstasy: The clinical, pharmacological and neurotoxicological effects ofthe drug MDMA. Boston: Kluwer Academic.Peroutka, S., Newman, H., & Harris, H. (1998). Subjective effects of 3,4-MDMA inrecreational abusers. Neuropsychopharmacology, 11, 273–277.Pope, H. G., & Yurgelun-Todd, D. (1996). The residual cognitive effects of heavy marijuanause in college students. JAMA, 275, 521–527.Rattray, M. (1991). Ecstasy: Towards an understanding of the biochemical basis of theactions of MDMA. Essays Biochem, 26, 77–87.Ricaurte, G. A., & McCann, U. D. (2001). Assessing long-term effects of MDMA(Ecstasy). Lancet, 358, 1831–1832.Ricaurte, G. A., McCann, U. D., Szabo, Z., & Scheffel, U. (2000). Toxicodynamics andlong-term toxicity of the recreational drug 3,4-methylenedicoxymethamphetamine(MDMA, “Ecstasy”). Toxicol Lett, 112–113, 143–146.Ricaurte, G. A., Yuan, J., Hatzidiitrious, G., Cord, B. J., & McCann, U. D. (2002).Severe dopaminergic neurotoxicity in primates after a common recreational doseregimen of MDMA (“Ecstasy”). Science, 297, 2260–2263.Rodgers, J. (2000). Cognitive performance amongst recreational users of “Ecstasy.” Psychopharmacology,151, 19–24.Sallan, S. E., Zinberg, N. E., & Frei, E. (1975). Antiemetic effect of delta-9-tetrahydrocannabinolin patients receiving cancer chemotherapy. N Engl J Med, 293,795–797.Schifano, F. (1991). Chronic atypical psychosis associated with MDMA (“Ecstasy”)abuse. Lancet, 338, 1335.Schwartz, R. (1991). Heavy marijuana use and recent memory impairment. PsychiatrAnn, 21, 80–83.Schwartz, R. H. (2002). Marijuana: A decade and a half later, still a crude drug withunderappreciated toxicity. Pediatrics, 109, 284–289.